TABLE 1.
Baseline Characteristics of Liver Recipients Who Received Prophylactic Treatment With HBIG Alone (Group 1) or in Combination With LAM or ADV (Group 2)∗
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.